title: Translating cancer trial endpoints into the language of managed care.
abstract: Oncology endpoints are an essential component of cancer trials, but often they are confusing, making it difficult to evaluate cancer therapies based on trial data. As more oncology agents hit the market and as indications expand for existing products, familiarity with these endpoints is critical for payers when making coverage decisions.
authors.affiliation: Allan Jay Kogan, MD, is vice president and regional medical director for Great-West Healthcare, in Dallas. Great-West is a Cigna company.Melinda Haren, RN, is director of business content for The Zitter Group, in Millburn, N.J.
authors.forename: Allan Jay
authors.initials: AJ
authors.lastname: Kogan
authors.forename: Melinda
authors.initials: M
authors.lastname: Haren